Diarrheal Diseases in Underdeveloped Countries - PowerPoint PPT Presentation

1 / 27
About This Presentation
Title:

Diarrheal Diseases in Underdeveloped Countries

Description:

Diarrhea and colitis due to tissue damage and influx of fluid. TechLab ... Pseudomembranous Colitis Caused by a Toxin A- Toxin B strain of Clostridium difficile ... – PowerPoint PPT presentation

Number of Views:44
Avg rating:3.0/5.0
Slides: 28
Provided by: TL10
Category:

less

Transcript and Presenter's Notes

Title: Diarrheal Diseases in Underdeveloped Countries


1
Diarrheal Diseases in Underdeveloped Countries
  • Worldwide Problem
  • More than 10,000 deaths per day
  • On average, about 18 diarrheal episodes per year
  • Primarily in children

2
Diarrheal Diseases in Developed Countries
  • Continues to be a problem
  • 25 million enteric infections per year
  • 10,000 deaths per year in the U.S.A
  • Highest rate in children under 5

3
Immunodiagnostics for Diarrheal Disease
Clostridium difficile Entamoeba
histolytica/dispar Giardia Cryptosporidium Clostri
dium perfringens Fecal Leukocytes Inflammatory
Bowel/Irritable Bowel
4
Clostridium difficile
5
  • Clostridium difficile is a gram positive, spore
    forming bacillus
  • Now known to be the cause of pseudomembranous
    colitis (PMC)and antibiotic associated
    diarrhea(AAD)
  • Causes almost all cases of PMC but only 25 of
    AAD. The most common cause of nosocomial diarrhea

6
  • Organism first described in 1935 - isolated from
    feces of normal infants and named Bacillus
    difficilis because of difficulty in isolation
  • Only recognized as a pathogen in late 1970s
  • Diarrhea is efficient method of spreading spores

7
In early 80s Dr Wilkins and his research team at
the Anaerobe Lab at Virginia Polytechnic
Institute (VPI) isolated and characterized toxin
A and toxin B of Clostridium difficile. Dr
Bartlett at Johns Hopkins University had
recognized that C.difficile produces two toxins
in 1980
8
  • Dr Wilkins research group also developed the
    first diagnostic test for the disease and
    developed and patented the antibodies
    subsequently used by all other companies for the
    development of their competitive EIAs.
  • The names Dr Wilkins and/or Dr Lyerly (the
    founders and co-owners of TechLab Inc) are to be
    found in the reference list of ALL competitive
    companies kit inserts

9
Clinical Terms
  • Antibiotic Associated Diarrhea
  • Antibiotic Associated Colitis
  • Pseudomembranous Colitis

10
Sequence of events leading to C.difficile
infection
  • Alteration of normal gut flora
  • Nosocomial infection by C.difficile
  • Growth and production of toxins
  • Tissue damage by toxin A, exacerbated by toxin B
  • Diarrhea and colitis due to tissue damage and
    influx of fluid

11
Biological Activities of Toxin A and B of
C.difficile
12
Are there unusual strains that may be missed with
an ELISA that detects only toxin A?
13
YES!
Multicenter Evaluation of the Clostridium
difficile TOX A/B TEST Journal of Clinical
Microbiology, Jan 1998, p. 184-190 An Outbreak of
Toxin A negative, Toxin B positive Clostridium
difficile Associated Diarrhea in a Canadian
Tertiary Care Hospital. Canada Communicable
Disease Report, April 1999 Characterization of a
Toxin A negative, Toxin B positive Strain of
Clostridium difficile Responsible for a
Nosocomial Outbreak of Clostridium difficile
Associated Diarrhea Journal of Clinical
Microbiology, July 2000, p. 2706-2714 Pseudomembra
nous Colitis Caused by a Toxin A- Toxin B strain
of Clostridium difficile Journal of Clinical
Microbiology, April 2000, p. 1696-1697
14
  • These strains have caused fatalities in Europe
    and North America
  • Actual incidence (at this time) is unknown - we
    believe it is around 10, however, a study in
    Israel showed an incidence of more than 66 in
    one hospital setting

15
  • These strains do not lack toxin A - they only
    lack the region of the toxin A gene that codes
    for the antibody binding site -known as the
    receptor region.

16
Analysis of A-B isolates by PCR
  • 52 A-/B isolates tested
  • All 52 were from clinical specimens that tested
    A-/B
  • All 52 have the same large deletion in Toxin A

A/B
A-/B
Antibody binding site-(repeat region)
Toxin B
Toxin A
17
All Broad Spectrum Antibiotics cause C.difficile
Infections
  • Not due to resistance of C.difficile
  • Due to susceptibility of normal flora
  • Diarrhea sometimes can be stopped by stopping the
    inciting agent

18
Epidemiology of C.difficile Disease
  • lt3 normal carrier rate in healthy adults
  • 50 or higher in infants
    usually asymptomatic
  • Outbreaks occur in hospitals and medical centers

19
Transmission of C.difficile
  • Primarily a nosocomial pathogen - however can be
    present in the community (mainly a disease of the
    aged)
  • Spore former - study showed that spores spread on
    floor of clean hospital room could be isolated
    and cultured months later
  • Has been isolated from hands of health care
    workers, library books, medical equipment, cords
    used to summon nurses, carpet etc.

20
Benefits of TechLab TOX A/B II TEST
  • Has highest correlation with tissue culture (gold
    standard), highly sensitive and specific
  • Detects both toxins
  • Diluent stabilizes toxin for transport or storage

21
Benefits of TechLab TOX A/B II TEST
  • Can be performed in as little as 40 minutes
    (rapid format)
  • Developed by the pioneers of C.difficile testing
    (Competitors use the TechLab patented monoclonal
    antibody)
  • No indeterminates, no repeat testing
  • Can be used with the TechLab stool preparation
    device to cut down on technician time and
    stabilize the toxin for transport

22
Clostridium difficile Testing
  • Culture
  • Latex agglutination
  • Tissue Culture
  • ELISA

23
Culture
  • Culturing is not standardized
  • Requires anaerobic techniques, special selective
    media and expertise not readily available in may
    labs
  • A toxin test has to be performed on the cultured
    isolates to determine whether the organisms is
    toxigenic or nontoxigenic
  • Organisms from asymptomatic patients can be
    isolated - these patients do not require
    antibiotic therapy
  • Organisms present in very low numbers can also be
    cultured - these may or may not cause disease

24
Latex Agglutination
  • Detects glutamate dehydrogenase, an enzyme
    produced by both toxigenic and nontoxigenic
    C.difficile and some other Clostridia
  • Very low sensitivity and specificity

25
Tissue Culture (Cytotoxicity Test)
  • Gold standard as it was the first test available
    and can detect picogram quantities of toxin B
    (remember, toxin B is the most potent cytotoxin
    known to man - toxin A is also cytotoxic but at
    the dilutions used in this test it has no
    cytotoxic effect).
  • Test requires that sample be diluted,
    centrifuged, filter sterilized and dispensed into
    the wells of a microtiter plate containing a
    confluent sheet of mammalian cells
  • Labor intensive and takes 24-48 hours for a
    result
  • Requires considerable expertise and specialized
    equipment

26
ELISA
Clostridium difficile Tests that are toxin A
specific
  • TechLab TOX A TEST
  • Meridian Premier Toxin A
  • Bartels Prima (recently purchased by Trinity)
  • Alexon ProspecT Toxin A
  • Vidas CDA
  • Becton Dickinson Culturette CD
  • Biosite Triage
  • Becton Dickinson ColorPac Toxin A

27
EIA TESTS that detect both toxin A and toxin B
  • TechLab TOX A/B TEST
  • Meridian Premier AB
Write a Comment
User Comments (0)
About PowerShow.com